HCA Healthcare Stock Price and Value Analysis

HCA Healthcare (NYSE:HCA) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold HCA Healthcare to reach your target.

Target type

HCA Free Cash Flow Trend

Free Cash Flow trendline for HCA
Free Cash Flow trendline for HCA Healthcare
CSV

Based on historical returns, we believe that HCA Healthcare can grow its free cash at a rate of about 8%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a decent rate.
  • This company has stable growth.
  • This company has a low dividend yield.
  • This company is less known than others.
  • This stock looks overpriced.

Inside the HCA Numbers

HCA Price
(HCA Healthcare stock price per share)
$475.57
[?] HCA Fair Price
(based on intrinsic value)
$368.54
[?] HCA Safety Price (based on a variable margin of safety) $221.12
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 22% lower than other Healthcare stocks
[?] PE Ratio versus Industry 61% higher than other Medical Care Facilities stocks
[?] Cash Yield 4.16%
[?] Free Cash Flow Jitter 16%
[?] Dividend Yield 0.66% (tax impact)
Shares Shorted 4,800,941

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-22.

The six months before that had 0 buys and 12 sales.

Recent Insider Activity

Open-market buys and sells reported by HCA Healthcare's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-02-18 McAlevey Michael R (EVP & Chief Legal & Admin Off.) Sell 1,694 $533.37
2026-02-11 Berres Jennifer (SVP & Chief Human Res. Officer) Sell 4,010 $503.00
2026-02-11 Berres Jennifer (SVP & Chief Human Res. Officer) Sell 4,010 $526.16
2026-02-11 Wyatt Christopher F. (SVP & Controller) Sell 4,000 $505.00
2026-02-03 HAZEN SAMUEL N (CEO) Sell 5,002 $502.15
2026-02-03 HAZEN SAMUEL N (CEO) Sell 7,395 $500.69
2026-02-03 HAZEN SAMUEL N (CEO) Sell 4,293 $498.12
2026-02-03 HAZEN SAMUEL N (CEO) Sell 5,162 $498.80
2026-02-03 HAZEN SAMUEL N (CEO) Sell 6,189 $500.02
2026-02-03 HAZEN SAMUEL N (CEO) Sell 14,716 $502.95

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 4,800,941 shares shorted. With 136,734,764 shares available for purchase and an average trading volume over the past 10 trading days of 1,181,570, it would take at least 4.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 860730 1,430
2010 860730 1,764
2011 860730 2,493
2012 860730 2,629
2013 860730 2,055
2014 860730 2,651
2015 860730 2,727
2016 860730 3,430
2017 860730 2,972
2018 860730 3,981
2019 860730 4,426
2020 860730 5,964
2021 860730 5,527
2022 860730 4,814
2023 860730 5,489
2024 860730 6,429
2025 860730 8,129

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $111,538 million against net income of $58,428 million, or 1.91 times.

In 2025, operating cash flow was 1.86 times net income, compared with 2.07 times for the earliest three years (2009 to 2011).

In 2025, capital expenditures were $4,944 million, 39.1% of operating cash flow of $12,636 million, which leaves an estimated $7,692 million after capex. Across the 17 years with reported capex, it averaged 46.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 1,054 2,747 1,317 2.61
2010 1,207 3,085 1,325 2.56
2011 2,465 3,933 1,679 1.60
2012 1,605 4,175 1,862 2.60
2013 1,556 3,680 1,943 2.37
2014 1,875 4,448 2,176 2.37
2015 2,129 4,734 2,375 2.22
2016 2,890 5,653 2,760 1.96
2017 2,216 5,426 3,015 2.45
2018 3,787 6,761 3,573 1.79
2019 3,505 7,602 4,158 2.17
2020 3,754 9,232 2,835 2.46
2021 6,956 8,959 3,577 1.29
2022 5,643 8,522 4,395 1.51
2023 5,242 9,431 4,744 1.80
2024 5,760 10,514 4,875 1.83
2025 6,784 12,636 4,944 1.86

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $51,162 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 8 of those years with dividend payment facts, dividends paid totaled $4,497 million, 10.0% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 8 of those 8 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $42,939 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $10,746 million, 132.2% of estimated free cash flow of $8,129 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 3,430 n/a 2,751 2,751 80.2%
2017 2,972 n/a 2,051 2,051 69.0%
2018 3,981 487 1,530 2,017 50.7%
2019 4,426 550 1,031 1,581 35.7%
2020 5,964 153 441 594 10.0%
2021 5,527 624 8,215 8,839 159.9%
2022 4,814 653 7,000 7,653 159.0%
2023 5,489 661 3,811 4,472 81.5%
2024 6,429 690 6,042 6,732 104.7%
2025 8,129 679 10,067 10,746 132.2%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $41,490 million in 2016 and $75,600 million in 2025, a compound annual growth rate of 6.9% over 9 years.

Revenue rose 7.1% from 2024 to 2025.

Our estimated free cash flow was $8,129 million in 2025, 10.8% of revenue. In 2016 the estimated margin was 8.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 41,490 3,430 8.3%
2017 43,614 2,972 6.8%
2018 46,677 3,981 8.5%
2019 51,336 4,426 8.6%
2020 51,533 5,964 11.6%
2021 58,752 5,527 9.4%
2022 60,233 4,814 8.0%
2023 64,968 5,489 8.4%
2024 70,603 6,429 9.1%
2025 75,600 8,129 10.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $1,040 million against total liabilities of $63,491 million, or 1.6% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 104.6% of total assets in 2025, compared with 140.5% in 2010, a decrease of 35.9 percentage points.

Stockholders equity was negative in 2025, at -$2,771 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 18.8% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 23,852 411 33,514 13,058
2011 26,898 373 32,668 -7,014
2012 28,075 705 36,416 -8,341
2013 28,594 414 35,759 -6,928
2014 30,980 566 37,478 -6,498
2015 32,744 741 38,790 -6,046
2016 33,758 646 39,391 -5,633
2017 36,593 732 41,588 -4,995
2018 39,207 502 42,125 -2,918
2019 45,058 621 45,623 -565
2020 47,490 1,793 44,598 2,892
2021 50,742 1,451 49,253 1,489
2022 52,438 908 52,511 -73
2023 56,211 935 55,151 1,060
2024 59,513 1,933 58,958 555
2025 60,720 1,040 63,491 -2,771

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $475.57, our model's value equals that price if free cash flow grows an average of 11.1 percent a year over the 10 projection years. Our model assumes 7.9 percent a year for this stock, so the price implies growth of 11.1 percent, which is above the 7.9 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $4,132 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $380.46 8.3%
Current price $475.57 11.1%
20 percent above the current price $570.68 13.4%
Our model (stored fair price) $368.54 7.9%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 17 fiscal years we have for HCA Healthcare under its current filer shows positive free cash flow.

Our fair value estimate for HCA Healthcare is $368.54, below its current price of $475.57.

Free cash flow from the first three years of data averaged $1,896 million, and from the last three $6,682 million: a sharp rise.

Year-to-year variability in free cash flow is fairly steady, measured at 16%.

HCA Healthcare pays a dividend yield of 0.66%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 22% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 61% above the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to HCA Healthcare, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
HCA Healthcare (HCA) 99,343 15.8 0.7% 4.2% 29% above
Tenet Healthcare Corporation (THC) 20,947 7.7 - 7.5% 21% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above
Universal Health Services (UHS) 10,345 7.5 0.5% 13.7% 71% below
DaVita (DVA) 10,129 12.2 - 14.7% 57% below
Surgery Partners (SGRY) 3,505 - - - 105% above
Progyny (PGNY) 2,630 32.8 - - 409% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 860730.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: HCA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in HCA

Does HCA Healthcare have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: HCA

This example shows how we apply the Trendshare checklist to HCA: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 475.57
    • Market cap: $99B
    • EPS: 30.15
  2. Step 2 — Valuation checks

    • P/E: 15.773
    • FCF yield: 4.2%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.